{"entity":{"id":"nct06524375","kind":"trial","name":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","aka":["BRAVE"],"tldr":"A phase 2 trial of Venetoclax in chronic lymphocytic leukaemia, run by Genentech, Inc., active and no longer recruiting.","summary":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period is a phase 2 interventional study registered as NCT06524375 by Genentech, Inc., with 118 participants enrolled, started 2024-08-09 and due to reach its primary completion in 2026-10-31. Interventions recorded: Venetoclax and cBTKi Monotherapy.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06524375","url":"https://clinicaltrials.gov/study/NCT06524375"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll","cll-treatment-naive"],"sections":[],"technologies":["bcl2-inhibitors","kinase-inhibitors"],"targets":[],"drugs":["venetoclax"],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06524375","phase":"2","setting":"Phase II, Open-label, Prospective Single-arm, Multi-center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKi For 1L CLL Can Achieve Deep Durable Remissions (by UMRD 10^-4) to Allow Off-treatment Period","sponsor":"Genentech, Inc.","started":"2024-08-09","startedType":"actual","enrolled":118,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06524375/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}